Navigation Links
Larynx preservation preferred over total laryngectomy
Date:2/1/2008

Patients with locally advanced laryngopharyngeal cancers who receive radical chemoradiation have significantly better voice outcomes during the 12 months following treatment when compared with patients who have undergone a total laryngectomy and surgical voice restoration, according to a study in the February 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

The conventional treatment for patients with advanced squamous carcinoma of the larynx has traditionally been a total laryngectomy, which is the removal of the voice box, with or without radiation; however, this treatment has several serious side effects, including natural-voice loss, altered food-swallowing function and a permanent opening in the trachea.

Researchers in this study, conducted jointly by the Royal Marsden Hospital Head and Neck Unit and The Institute of Cancer Research, both in London, sought to determine if larynx preservation through chemoradiation would result in improved voice results and serve as a suitable alternative to total laryngectomy, which, in turn, would remove the need for surgery and all of the related potential side effects and risks.

Twenty-one patients, both male and female, with a median age of 65 years old, who were diagnosed with Stage III or IV laryngopharyngeal cancer, were given induction chemotherapy followed by radical chemoradiation. The researchers then used electroglottography placing electrodes alongside the larynx to electronically record and analyze the voice function of the patients before treatment and at one, six and 12 months after treatment. This is the first study of its kind to use electroglottography as an assessment technique.

Patients were asked to read a standard passage and pronounce vowel sounds into a microphone that sat at the same distance from the mouth of each patient. The researchers then used these recordings to measure jitter in the voice, maximum phonation time and words per minute.

Single voice recordings were also taken from 21 patients, with a median age of 65 years old, who received a total laryngectomy and surgical voice restoration, as well as from 21 normal controls of the same median age group.

The researchers found that preservation of the larynx through chemoradiation did not always return voice quality to exactly how it was before the tumor was present, but it did provide for significantly better voice outcomes when compared to removing the larynx through surgery. At 12 months after treatment, the patients receiving chemoradiation had normal maximum phonation time and words per minute, but less than normal jitter.

This study is important because it offers patients reassurance that if they undergo organ preservation, it is statistically proven that their voice will be better than if they undergo surgery. We can reassure patients that their voice is likely to recover from the immediate effects of chemoradiation, said Kevin Harrington, M.B.B.S., clinical senior lecturer at The Institute of Cancer Research. This study should also allay the concerns of surgeons that laryngopharyngeal cancer patients cannot be successfully treated with chemoradiation with good functional outcome.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Therapeutic Radiology and Oncology
Source:Eurekalert

Related medicine news :

1. New research suggests hearts are experts at self-preservation
2. The aye-ayes have it: The preservation of color vision in a creature of the night
3. Mylan Declares Quarterly Preferred Stock Dividend
4. NHP Increases Its Quarterly Common Dividend by $0.03 and Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
5. Wyeth Declares Common and Preferred Stock Dividends
6. Smart Balance Announces Conversion of Convertible Preferred Stock
7. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo
10. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
(Date:5/31/2016)... ... ... Interest is on the rise for using the CRISPR-Cas9 system for functional ... hit validation. A key reason may be that high-throughput synthesis—combined with a proprietary algorithm ... collections in arrayed formats. , Arrayed crRNA screens have the advantage ...
(Date:5/31/2016)... ... May 31, 2016 , ... MinerEye ... Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each year, Gartner ... research reports evaluating these innovative vendors and their products and services. , According ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... media enterprise focused on patients with cancer, has added Cancer and Careers ... website visitors with more timely content on continuing successful careers while fighting cancer. ...
(Date:5/30/2016)... Salt Lake City, Utah (PRWEB) , ... May ... ... health insurance reimbursement for small businesses, announced today the publication of an original ... helps business owners and health insurance professionals understand how Zane Benefits complies with ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 LabStyle ... Dario™ Diabetes Management Tool, today announced that the Company,s Chief ... Marcum MicroCap Conference being held June 1-2 in ... being held June 7-9 in Los Angeles, CA. ... discuss recent corporate and operational milestones, including the U.S. FDA ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
Breaking Medicine Technology: